9 completed, 2 not yet recruiting, 1 recruiting. 12 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 9, Not yet recruiting 2, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Racivir: new trials by email Literature Review of Racivir trials Research Report on Racivir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISL, Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL, Continue SoC ART - Epigenetic Aging | Phase 2 | Not yet recruiting | The University of Texas Health Science Center, Houston | 60 | 2026-10-30 | 2026-10-23 |
| A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC) - HIV Infections | Phase 2 | Recruiting | ViiV Healthcare | 186 | 2026-02-11 | 2026-07-23 |
| Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI, Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) - HIV Infections, HBV Coinfection | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 140 | 2025-02-01 | 2025-02-05 |
| The Women TAF-FTC Benchmark Study co-formulated 25mg TAF/ 200mg FTC - HIV Infections | Phase 2 / Phase 3 | Completed | University of Washington | 54 | 2023-04-10 | 2026-06-18 |
| The Women TDF-FTC Benchmark Study co-formulated 300 mg TDF/ 200mg FTC - HIV Infections | Phase 2 | Completed | University of Washington | 72 | 2022-04-25 | 2026-06-15 |
| Pre-Exposure Prophylaxis in YMSM coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP, Placebo, Many Men, Many Voices (3MV) - HIV | Phase 2 | Completed | University of North Carolina, Chapel Hill | 68 | 2009-08-01 | 2017-04-17 |
| Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875) Vicriviroc, emtricitabine and tenofovir disoproxil fumarate - HIV Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 218 | 2007-12-01 | 2015-02-06 |
| Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA) Tenofovir (TDF), Emtricitabine (FTC) - HIV Infection, Pregnancy | Phase 2 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | 72 | 2006-10-01 | 2011-12-05 |
| Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects Racivir, a non-nucleoside reverse transcriptase inhibitor - HIV Infections | Phase 2 | Completed | Pharmasset | 60 | 2004-09-01 | 2007-07-03 |
| Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV) - HIV Infections | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 266 | 2002-08-01 | 2021-11-05 |
| Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs Didanosine (ddI), Efavirenz (EFV), Emtricitabine (FTC) - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 43 | 2001-08-01 | 2021-11-05 |
| Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults emtricitabine, FTC (drug), didanosine, ddI (drug), efavirenz (drug) - HIV Infections, Antiretroviral Naive | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 39 | 1999-02-01 | 2026-06-15 |
HIV Infections (10)
ANRS, Emerging Infectious Diseases (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Washington (2) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Merck Sharp & Dohme LLC (1) · Pharmasset (1) · The University of Texas Health Science Center, Houston (1) · University of North Carolina, Chapel Hill (1) · ViiV Healthcare (1)
United States (6) · Argentina (2) · France (2) · Kenya (2) · Puerto Rico (2) · Australia (1) · Belgium (1) · Cambodia (1) · Canada (1) · Côte d’Ivoire (1) · Germany (1) · Italy (1) · Japan (1) · Mexico (1) · Panama (1)
Kenneth K Mugwanya, MBChB, MS, PhD (2) · Peter L Anderson, PharmD (2) · Ross E. McKinney, Jr., MD (2) · Ann J. Melvin, MD (1) · Didier K Ekouevi, MD, PhD (1) · Genevieve Chene, MD, PhD (1) · Jean-Michel Molina, MD, PhD (1) · Jordan E Lake, MD, MSc (1) · Julie Bottero (1) · Mobeen H. Rathore, MD (1) · Robert Murphy, MD (1) · Sybil Hosek, PhD (1)
PMID 17591032, PMID 18981766, PMID 18987623, PMID 19104016, PMID 19307941, PMID 21288774, PMID 38860025, PMID 40924774
2025 (1), R01AI155086 (1)